Dr. Joseph E. Burris, MD
Physical Medicine & Rehabilitation (PM&R) (Physical Medicine & Rehabilitation Physician)
315 W Business Loop 70
Columbia, MO 65203
Who else practices at this address →
Boone County is a federal dental shortage area. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Kansas School of Med (Kc/Wich/Sal) (1997)
- Years since graduation
- 29
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 232
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1997Medical school: University of Kansas School of Med (Kc/Wich/Sal)
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Physical Medicine & Rehabilitation Physician primary
MO license 115634
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Map: Physical Medicine & Rehabilitation (PM&R) per capita by county →
Where they work
Hospitals
- University of Missouri Health Care Columbia, MO
Medical groups
- The Curators of the University of Missouri (1,131 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 232
- Services billed
- 727
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 455 | 182 |
| Needle measurement of electrical activity in muscle with injection of chemical for paralysis of nerve muscle | 98 | 33 |
| Established patient office or other outpatient visit, 40-54 minutes | 78 | 52 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 5 or more muscles, first extremity | 62 | 24 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, each additional extremity | 40 | 14 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, first extremity | 36 | 11 |
| Hospital discharge day management, 30 minutes or less | 30 | 30 |
| Established patient office or other outpatient visit, 30-39 minutes | 26 | 23 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 24 | 24 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Baclofen Other prescribers in Columbia, MO | 106 |
| Gabapentin Other prescribers in Columbia, MO | 95 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Columbia, MO | 15 |
| Tramadol Hcl Other prescribers in Columbia, MO | 13 |
| Amantadine (amantadine hcl) Other prescribers in Columbia, MO | 13 |
| Morphine Sulfate Other prescribers in Columbia, MO | 13 |
| Morphine Sulfate Er (morphine sulfate) Other prescribers in Columbia, MO | 13 |
| Sertraline Hcl Other prescribers in Columbia, MO | 12 |
| Memantine Hcl Other prescribers in Columbia, MO | 12 |
| Alprazolam Other prescribers in Columbia, MO | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 6 payments worth $2,410 in total to this clinician.
| AbbVie Inc. | $2,316 |
|---|---|
| E.r. Squibb & Sons, L.l.c. | $68.58 |
| Ipsen Biopharmaceuticals, Inc | $24.62 |
| Compensation for services other than consulting (speaking, faculty) | $2,300 |
|---|---|
| Food and Beverage | $110 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. May 2, 2025 | Compensation for services other than consulting (speaking, faculty) BOTOX · NEUROSCIENCE | $863 |
| AbbVie Inc. Nov 6, 2025 | Compensation for services other than consulting (speaking, faculty) BOTOX · NEUROSCIENCE | $863 |
| AbbVie Inc. May 12, 2025 | Compensation for services other than consulting (speaking, faculty) BOTOX · NEUROSCIENCE | $575 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $204,242 in research payments for these studies, mostly to the institutions running them.
- Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of NT 201 in the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury in Adu…
Merz Pharmaceuticals, LLC - A Study to Estimate How Often Post-stroke Spasticity Occurs and to Provide a Standard Guideline on the Best Way to Monitor Its Development
Ipsen Pharma Sas · Active, not recruiting · NCT06055725 - M23-499 - Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Spasticity
AbbVie Inc. - A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults With Upper Limb Spasticity.
Ipsen Pharma Sas · Completed · NCT04936542 - A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity
Pacira Pharmaceuticals Incorporated
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.